ArticleChemical science2025
PVAylation: precision end-functionalized poly(vinyl alcohol) for site-selective bioconjugation.
Article in Chemical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The (bio)conjugation of polymers onto proteins enhances their pharmacokinetics and stability, most commonly using PEG (polyethylene glycol), but there is a need for alternatives. Poly(vinyl alcohol), PVA, is a water-soluble, biocompatible and environmentally degradable polymer, which also has the unique function of ice recrystallisation inhibition (IRI) which can aid the cryopreservation of biologics. Site-specific PVA bioconjugation ("PVAylation") is underexplored due to the challenge of obtaining homogenous mono end-functional PVA. Here we show that following deprotection of the acetate (from the precursor poly(vinyl acetate)), the concurrent xanthate end-group reduction leads to a diversity of ambiguous end-groups which prevented precision conjugation. This is overcome by using a photo-catalyzed reduction of the omega-terminal xanthates to C-H, which is orthogonal to active-ester bioconjugation functionality at the alpha-chain terminus, demonstrated by MALDI-TOF mass spectrometry. This strategy enabled the preparation of well-defined mono-functional PVA displaying alkyne, biotin and O
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.